Overview Dividends

(GRAL) GRAIL - Ratings and Ratios

Exchange: NASDAQ • Country: United States • Currency: USD • Type: Common Stock • ISIN: US3847471014

Diagnostic, Screening, Cancer, Blood

Description: GRAL GRAIL

GRAIL, LLC (NASDAQ:GRAL) is a US-based biotechnology company. The stock has been exhibiting significant price movements, with key support and resistance levels identified at $32.1, $30.0, $27.9 and $41.0, $38.0, $35.9, $33.8 respectively.

To better understand the companys financial health, we can examine key performance indicators (KPIs) such as revenue growth, R&D expenses, and cash burn rate. Given GRAILs focus on biotechnology, its likely that R&D expenses are substantial. A closer look at the quarterly tax provision data may reveal insights into the companys earnings and profitability.

The biotechnology industry is driven by factors such as innovation, regulatory approvals, and market demand for new treatments. Key economic drivers include government funding for healthcare, patent expirations, and competition from established players. GRAILs market capitalization of $1.169 billion USD suggests a significant presence in the industry.

With a negative Return on Equity (RoE) of -18.04, GRAIL is likely in an investment phase, prioritizing growth over profitability. The absence of a P/E ratio further supports this notion, as the company may not be generating earnings. To assess the companys prospects, we should examine its pipeline, clinical trial progress, and strategic partnerships.

GRAL Stock Overview

Market Cap in USD 1,234m
Sub-Industry Biotechnology
IPO / Inception 2024-06-25

GRAL Stock Ratings

Growth Rating 90.5%
Fundamental 26.8%
Dividend Rating -
Return 12m vs S&P 500 138%
Analyst Rating 3.50 of 5

GRAL Dividends

Currently no dividends paid

GRAL Growth Ratios

Growth Correlation 3m -81.5%
Growth Correlation 12m 80.6%
Growth Correlation 5y 81.6%
CAGR 5y 68.86%
CAGR/Max DD 5y 1.13
CAGR/Mean DD 5y 2.51
Sharpe Ratio 12m -0.55
Alpha 165.42
Beta 0.926
Volatility 60.28%
Current Volume 1147.8k
Average Volume 20d 666.4k
Stop Loss 35.9 (-6.1%)
Signal 1.74

Piotroski VR‑10 (Strict, 0-10) 0.0

Net Income (-443.0m TTM) > 0 and > 6% of Revenue (6% = 8.06m TTM)
FCFTA -0.22 (>2.0%) and ΔFCFTA -2.93pp (YES ≥ +1.0pp, WARN ≥ +0.5pp)
NWC/Revenue 432.8% (prev 847.9%; Δ -415.1pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp)
CFO/TA -0.14 (>3.0%) and CFO -370.0m > Net Income -443.0m (YES >=105%, WARN >=100%)
NO Net Debt/EBITDA fails (EBITDA <= 0)
Current Ratio 9.23 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active)
Outstanding Shares last Quarter (35.1m) change vs 12m ago 12.90% (target <= -2.0% for YES)
Gross Margin -5.43% (prev -77.95%; Δ 72.52pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0)
Asset Turnover 4.50% (prev 3.36%; Δ 1.14pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0)
error: Interest Coverage Ratio cannot be calculated (needs EBITDA TTM and Interest Expense TTM)

Altman Z'' -39.22

(A) 0.22 = (Total Current Assets 651.8m - Total Current Liabilities 70.6m) / Total Assets 2.70b
(B) -3.71 = Retained Earnings (Balance) -10.02b / Total Assets 2.70b
warn (B) unusual magnitude: -3.71 — check mapping/units
(C) -0.21 = EBIT TTM -626.9m / Avg Total Assets 2.99b
(D) -25.83 = Book Value of Equity -10.02b / Total Liabilities 387.9m
Total Rating: -39.22 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D)

ValueRay F-Score (Strict, 0-100) 26.75

1. Piotroski 0.0pt = -5.0
2. FCF Yield -60.51% = -5.0
3. FCF Margin data missing
4. Debt/Equity 0.14 = 2.49
5. Debt/Ebitda -0.70 = -2.50
6. ROIC - WACC -32.98% = -12.50
7. RoE -18.04% = -2.50
8. Rev. Trend 87.91% = 4.40
9. Rev. CAGR 0.0% = 0.0
10. EPS Trend -5.58% = -0.14
11. EPS CAGR -98.90% = -2.50

What is the price of GRAL shares?

As of September 09, 2025, the stock is trading at USD 38.23 with a total of 1,147,785 shares traded.
Over the past week, the price has changed by +20.94%, over one month by +16.48%, over three months by -4.50% and over the past year by +186.58%.

Is GRAIL a good stock to buy?

No, based on ValueRay´s Fundamental Analyses, GRAIL (NASDAQ:GRAL) is currently (September 2025) a stock to sell. It has a ValueRay Fundamental Rating of 26.75 and therefor a negative outlook according to the companies health.
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of GRAL is around 39.67 USD . This means that GRAL is currently overvalued and has a potential downside of 3.77%.

Is GRAL a buy, sell or hold?

GRAIL has received a consensus analysts rating of 3.50. Therefor, it is recommend to hold GRAL.
  • Strong Buy: 1
  • Buy: 0
  • Hold: 3
  • Sell: 0
  • Strong Sell: 0

What are the forecasts/targets for the GRAL price?

Issuer Target Up/Down from current
Wallstreet Target Price 40.5 5.9%
Analysts Target Price 40.5 5.9%
ValueRay Target Price 43.8 14.6%

Last update: 2025-08-26 02:47

GRAL Fundamental Data Overview

Market Cap USD = 1.23b (1.23b USD * 1.0 USD.USD)
CCE Cash And Equivalents = 602.8m USD (Cash And Short Term Investments, last quarter)
P/S = 9.1915
P/B = 0.5332
Beta = None
Revenue TTM = 134.3m USD
EBIT TTM = -626.9m USD
EBITDA TTM = -469.8m USD
Long Term Debt = 317.3m USD (from nonCurrentLiabilitiesTotal, last quarter)
Short Term Debt = 13.7m USD (from shortTermDebt, last quarter)
Debt = 331.0m USD (Calculated: Short Term 13.7m + Long Term 317.3m)
Net Debt = -65.3m USD (from netDebt column, last quarter)
Enterprise Value = 962.5m USD (1.23b + Debt 331.0m - CCE 602.8m)
Interest Coverage Ratio = unknown (Ebit TTM -626.9m / Interest Expense TTM 0.0)
FCF Yield = -60.51% (FCF TTM -582.4m / Enterprise Value 962.5m)
FCF Margin = -433.7% (FCF TTM -582.4m / Revenue TTM 134.3m)
Net Margin = -329.9% (Net Income TTM -443.0m / Revenue TTM 134.3m)
Gross Margin = -5.43% ((Revenue TTM 134.3m - Cost of Revenue TTM 141.6m) / Revenue TTM)
Tobins Q-Ratio = -0.10 (set to none) (Enterprise Value 962.5m / Book Value Of Equity -10.02b)
Interest Expense / Debt = 0.0% (Interest Expense 0.0 / Debt 331.0m)
Taxrate = 21.0% (US default)
NOPAT = -626.9m (EBIT -626.9m, no tax applied on loss)
Current Ratio = 9.23 (Total Current Assets 651.8m / Total Current Liabilities 70.6m)
Debt / Equity = 0.14 (Debt 331.0m / last Quarter total Stockholder Equity 2.31b)
Debt / EBITDA = -0.70 (Net Debt -65.3m / EBITDA -469.8m)
Debt / FCF = -0.57 (Debt 331.0m / FCF TTM -582.4m)
Total Stockholder Equity = 2.45b (last 4 quarters mean)
RoA = -16.39% (Net Income -443.0m, Total Assets 2.70b )
RoE = -18.04% (Net Income TTM -443.0m / Total Stockholder Equity 2.45b)
RoCE = -22.62% (Ebit -626.9m / (Equity 2.45b + L.T.Debt 317.3m))
RoIC = -25.54% (NOPAT -626.9m / Invested Capital 2.45b)
WACC = 7.44% (E(1.23b)/V(1.57b) * Re(9.43%)) + (D(331.0m)/V(1.57b) * Rd(0.0%) * (1-Tc(0.21)))
Shares Correlation 5-Years: 0.0 | Cagr: -29.00%
Discount Rate = 9.43% (= CAPM, Blume Beta Adj.)
Fair Price DCF = unknown (Cash Flow -582.4m)
Revenue Correlation: 87.91 | Revenue CAGR: 0.0%
Rev Growth-of-Growth: -18.48
EPS Correlation: -5.58 | EPS CAGR: -98.90%
EPS Growth-of-Growth: 52.36

Additional Sources for GRAL Stock

News: Wall Street Journal | Benzinga | Yahoo Finance
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle